<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529239</url>
  </required_header>
  <id_info>
    <org_study_id>036033</org_study_id>
    <nct_id>NCT04529239</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetes Glucose Biomarker Study With a Continuous Glucose Monitoring System</brief_title>
  <official_title>A Triple Cohort, Prospective Observational Study to Analyze Type 2 Diabetes Glucose Biomarkers With a Continuous Glucose Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klick Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mittal Global Clinical Trial Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klick Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current gold standard methodologies for diagnosing type 2 diabetes (T2D) or prediabetes can&#xD;
      be unreliable and inaccurate, and require the need for multiple different tests for&#xD;
      comparison. It is possible that a simpler and more refined method of diagnosing T2D or&#xD;
      prediabetes involves examining the proportional-integral (PI) control system of the body's&#xD;
      glycemic function (i.e., a model of the glucose curve). The purpose of this research is to&#xD;
      examine how well a PI model can diagnose nondiabetic, prediabetic, or diabetic patients based&#xD;
      on glucose data gathered from a wearable glucose monitoring device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose biomarker data from the continuous glucose monitoring device, which will be analyzed as a function of different homeostasis responses from the 3 different cohorts of individuals (i.e., i) low to moderate risk; ii) high risk, iii) very high risk).</measure>
    <time_frame>The device is worn for 14 days on each participant</time_frame>
    <description>Continuous glucose data from the FreeStyle Libre device will be collected from each individual and analyzed for differences in glucose responses (i.e., &quot;ups&quot; and &quot;downs&quot;) across the different study groups.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Low to Moderate Risk</arm_group_label>
    <description>The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <description>The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very High Risk</arm_group_label>
    <description>The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abbott Freestyle Libre Pro</intervention_name>
    <description>Continuous glucose monitoring device to analyze diabetes biomarkers.</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Low to Moderate Risk</arm_group_label>
    <arm_group_label>Very High Risk</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to collect glycated hemoglobin (HbA1c) measurements, fasting plasma glucose&#xD;
      (FPG), and plasma glucose during an oral glucose tolerance test (OGTT).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults and those at risk of developing prediabetes or type 2 diabetes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Either male or non-pregnant, non-lactating female aged &gt; 18-60 &lt;years (both inclusive)&#xD;
&#xD;
          -  Subjects willing to give written informed consent&#xD;
&#xD;
          -  Healthy Volunteers&#xD;
&#xD;
          -  Subjects able to comply with the study protocol&#xD;
&#xD;
          -  Women of child bearing potential must have a negative urine pregnancy test prior to&#xD;
             study entry&#xD;
&#xD;
          -  Minimum 4 subjects in each interval of approx 7 years&#xD;
             (18-25/26-32/32-38/39-45/46-52/53-59)&#xD;
&#xD;
          -  Minimum 40% subjects of one gender to mark relative distribution&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any person below the age of 18 years&#xD;
&#xD;
          -  Suspected or confirmed pregnancy&#xD;
&#xD;
          -  Currently breastfeeding&#xD;
&#xD;
          -  Diagnosis of any known chronic or acute medical disease of any kind (e.g.,&#xD;
             cardiovascular disease, respiratory disease, influenza, pneumonia, etc.)&#xD;
&#xD;
          -  Diagnosis of any known neurological disease or psychological disorder of any kind&#xD;
             (e.g., brain lesion, epilepsy, anxiety, eating disorder, mood disorder, sleep&#xD;
             disorder, etc.)&#xD;
&#xD;
          -  Any implanted electrical medical device (e.g., pacemaker, insulin pump, deep brain&#xD;
             stimulator, etc.)&#xD;
&#xD;
          -  Any form of prescription medication&#xD;
&#xD;
          -  Use of antibiotics in the three months prior to enrollment&#xD;
&#xD;
          -  Any person planning to undergo a Magnetic Resonance Imaging (MRI), Computed Tomography&#xD;
             (CT) scan, or high-frequency electrical heat (diathermy) treatment during the duration&#xD;
             of the study (as per restrictions of the FreeStyle Libre pro device)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Klick Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 3R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>November 14, 2020</last_update_submitted>
  <last_update_submitted_qc>November 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

